VanEck Vectors Generic Drugs ETF
GNRX
GNRX was delisted on the 4th of April, 2019.
4 hedge funds and large institutions have $122K invested in VanEck Vectors Generic Drugs ETF in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
87% less capital invested
Capital invested by funds: $916K → $122K (-$794K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$4.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$716K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $64K | -$716K | -32,000 | -91% |
|
|
IA
2
IFP Advisors
Tampa,
Florida
| $48K | – | – | – |
|
|
NFG
3
Next Financial Group
Houston,
Texas
| $6K | – | – | – |
|
|
LTFS
4
Ladenburg Thalmann Financial Services
Miami,
Florida
| $4K | +$4.47K | +200 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| – | -$6K | -240 | Closed |
|
GNRX Hedge Fund Activity: Q4 2016 in Review
4 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q4 2016, worth a combined $122K — down 87% from $916K a quarter earlier.
Fund positioning in GNRX was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Ladenburg Thalmann Financial Services, opening a new position worth an estimated $4.47K. The largest seller was UBS Group, cutting an estimated $716K.
- 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $122K of VanEck Vectors Generic Drugs ETF stock for Q4 2016, down 87% quarter-over-quarter.
- 1 fund opened new VanEck Vectors Generic Drugs ETF positions in Q4 2016 and 1 closed out, a net change of 0 holders.
- The largest VanEck Vectors Generic Drugs ETF buyer in Q4 2016 was Ladenburg Thalmann Financial Services, an estimated $4.47K added.
- The largest VanEck Vectors Generic Drugs ETF seller in Q4 2016 was UBS Group, an estimated $716K sold.
Based on aggregated 13F filings for Q4 2016.